ホーム › 非小細胞肺癌 › テキサス › League City
League City、TXにおける非小細胞肺癌の臨床試験
League Cityとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する15件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
被験者募集中第1相
- The University of Texas, MD Anderson Cancer Center - League City, League City
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
被験者募集中第3相
- University Of Texas Medical Branch At Galveston, Galveston · 23マイル先
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
被験者募集中第3相
- The University of Texas, MD Anderson Cancer Center - League City, League City
- Texas Oncology - Gulf Coast, Webster · 3マイル先
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Kelsey-Seybold Clinic - Bay Area Campus Building A, Webster · 3マイル先
- Kelsey-Seybold Clinic - Bay Area Campus Building B, Webster · 3マイル先
- Kelsey-Seybold Clinic - Bay Area Campus Building C, Webster · 3マイル先
- 他1件
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Texas Oncology-Gulf Coast, Webster · 3マイル先
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Galveston · 23マイル先
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- University of Texas Medical Branch, Galveston · 23マイル先
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
被験者募集中第3相
- The University of Texas, MD Anderson Cancer Center - League City, League City
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
被験者募集中第3相
- Local Institution - 0692, Galveston · 23マイル先
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Webster · 3マイル先
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- USO - Texas Oncology, Webster · 3マイル先
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
被験者募集中第3相
- Research Site, Webster · 3マイル先
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Tranquil Clinical Research, Webster · 3マイル先
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
被験者募集中第2相
- MD Anderson League City, League City
PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study
被験者募集中
- University of Texas Medical Branch at Galveston, Galveston · 23マイル先
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
League Cityにおける他の研究
- 乳がん12件の研究
- 転移性癌7件の研究
- 潰瘍性大腸炎6件の研究
- 肺がん6件の研究
- 大腸癌6件の研究
- がん（全種類）5件の研究
- 卵巣がん5件の研究
- 脳卒中5件の研究
- 膀胱癌4件の研究
- 頭頸部扁平上皮癌4件の研究
- 前立腺がん4件の研究
- コロナ後遺症（ロングコビッド）3件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。